|
Scam Alert
The Division of Consumer Affairs (Division) is warning all licensed professionals about individuals impersonating New Jersey Division of Consumer Affairs (DCA) investigators, Drug Enforcement Administration (DEA) agents, DEA investigators, New Jersey Drug Control Unit investigators, Federal Bureau of Investigation (FBI) investigators, and other law enforcement personnel, as part of an extortion scheme.
The impersonators are contacting licensees by telephone or letter, stating that they are the subject of an investigation. The callers are demanding money to clear up the matter, or threatening to revoke the individual's license. Please be advised that the Division of Consumer Affairs will not contact licensees by telephone to discuss investigations or demand money. Anyone receiving a telephone call from a person purporting to be any of the above mentioned individuals seeking money, should refuse the demand. We encourage you to report the call to the Federal Trade Commission (FTC) at
ReportFraud.ftc.gov. You may also report the call to the Division at
AskConsumerAffairs@lps.state.nj.us.
|
|
Physician Obligations Regarding Death Certificates
Recently, the Board of Medical Examiners has seen an uptick in consumer complaints alleging that physicians have failed to timely complete death certificates. The failure to timely complete death certificates invariably causes hardships for surviving families. The absence of a death certificate not only can occasion delays in the ability to make funeral arrangements and to timely complete burials or cremations, but also unnecessarily exacerbates the considerable emotional strain and toll felt by grieving family and friends following the death of a loved one.
Please be reminded that Board of Medical Examiners licensees must comply with Board regulations regarding the pronouncement of death, the entry of required information into the
New Jersey Electronic Death Registration System (NJ-EDRS), and the completion of death certificates. Death certificates must be prepared and completed within a reasonable period of time, not to exceed 24 hours after the pronouncement of death. See
NJAC 13:35-6.2(g). The attending or covering physician (See
NJAC 13:35-6.2(a)) must use the NJ-EDRS to provide the required information. See
NJAC 13:35-6.2(h).
While we recognize that there are myriad responsibilities placed on practicing physicians, we underscore the importance of a physician's obligation to facilitate the prompt entry of data into the NJ-EDRS and completion of a death certificate. Licensees are urged to acquaint themselves with using the NJ-EDRS in order to meet this obligation. Hospitals and other health care facilities may have designated personnel who can assist with the process. Licensees are cautioned that failure to comply with the regulation may subject them to professional discipline. |
|
Use of Mifepristone
We have reviewed the April 14, 2023 statement from Attorney General Platkin on the prescribing, dispensing and administration of mifepristone by licensed health care practitioners. We recognize the need for patients to have access to prescribed medication and acknowledge the responsibility of pharmacists and pharmacies to fill valid prescriptions pursuant to N.J.S.A. 45:14-67.1. This Board will exercise its administrative and prosecutorial discretion and will not discipline licensees who dispense mifepristone in a manner consistent with the standards and conditions that were recognized nationally prior to the recent decisions and Orders entered by the Texas District Court, Washington District Court and the Fifth Circuit Court of Appeals. This policy statement shall remain in full force and effect until such time as there is clarity of law on standards and conditions for use of mifepristone in this State.
Click here to view the statement from Attorney General Matthew J. Platkin on the use of mifepristone by licensed medical professionals.
|
|
Emergency Adopted Rules - Prescribing CDS and Management of Acute and Chronic Pain
On March 1, 2017, the Attorney General and the Board of Medical Examiners adopted emergency amendments to the rules in N.J.A.C. 13:35-2A.14, 2B.12, and 7.6, concerning limitations on prescribing, administering, or dispensing of controlled dangerous substances, with specific limitations for opioid drugs, and establishing special requirements for the management of acute and chronic pain. These limitations and requirements apply to physicians, podiatrists, physician assistants, and certified nurse midwives.
These amendments are effective immediately and will remain in effect for 60 days. Click the link below to view the text of the emergency adopted amendments. These emergency rules also are being concurrently proposed for readoption in order to permit members of the regulated community and the general public to submit comments concerning the rules and the intention of the Attorney General and Board to make these amendments permanent. Comments may be submitted following publication of the concurrent proposal in the New Jersey Register. Click the link below to view a copy of the Emergency Adoption and Concurrent Proposal filed with the Office of Administrative Law.
The official version of the Emergency Adoption and Concurrent Proposal will be published in the New Jersey Register on March 20, 2017
View Information (3/2/17)
|
|
Electronic Prescribing of Controlled Substances (EPCS) for a Practitioner
On January 7, 2013 the Board of Pharmacy and Drug Control Unit adopted rules to allow prescribers to issue Schedule II controlled substances prescript ions electronically in accordance with federal requirements. New Jersey practitioners and pharmacies can utilize EPCS for all patient prescriptions.
View EPCS Information
(10/5/2015) |
|
Physician Issuance of Multiple Prescriptions for Schedule II Controlled Substances
The New Jersey Division of Consumer Affairs is re-issuing the following guidance regarding the issuance of multiple prescriptions of a Schedule II controlled dangerous substance by a physician to a patient
View Guidance (10/5/15) |
|
Information About the New NJ PMP Law.
In July, Senate Bill 1998 was signed into law (P.L.2015, c.74) which substantially revises the scope and expands the capabilities of the New Jersey Prescription Monitoring Program (NJPMP). The Division of Consumer Affairs is tasked with implementing the new law, which takes effect on November 1, 2015.
View Notice
(9/2015) |
|
Student-Athlete Cardiac Assessment Professional Development Module
(PD module)
The New Jersey Department of Education (NJDOE) is pleased to announce the availability of the
Student-Athlete Cardiac Assessment professional development module (PD module) required by the
Scholastic Student-Athlete Safety Act (P.L. 2013, c.71). Physicians, advanced practice nurses and physician assistants are required to complete the PD module before performing any student-athlete pre-participation physical examination prior to the first official practice of the athletic season starting with the 2015-16 school year. The legislation required the development of the PD module to increase the assessment skills of the health care providers who perform student-athlete physical examinations and screenings. The PD module can be found
here. Additionally, the legislation
requires that the American Academy of Pediatrics, the New Jersey Academy of Family Physicians, the American Heart Association, the American College of Cardiology, the Athletic Trainer’s Society of New Jersey, the State Board of Medical Examiners, the New Jersey State Board of Nursing and the New Jersey State Society of Physician Assistants to post the link to the PD module on their respective websites and also the link to the
Sudden Cardiac Death in Young Athletes pamphlet. If you have any questions, please direct them
here. |
|
State Board of Medical Examiners Ebola Policy
Board licensees have long adhered to a tradition of care. A licensee of this Board may not categorically refuse to treat a patient who has been diagnosed with Ebola, or who has not been diagnosed with Ebola but who is symptomatic of the disease, when the licensee possesses the skill and experience to treat the condition presented, and when the licensee has been appropriately trained in the proper care of such patients, and having been provided with, and trained in the use of, personal protective equipment ("PPE"). The Board, however, recognizes that certain health care workers with certain physical conditions may be unduly susceptible to the virus and should refrain from direct care of such patients. The Board will consider each case on an individual basis giving due consideration to any such extenuating circumstances. Even where such extenuating circumstances exist, however, the licensee retains the responsibility to make alternate arrangements for the proper care of the patient. To learn more about appropriate training and equipment please go to the
NJDOH Ebola/Viral Hemorrhagic Fever Information Page. |
|
"Notification of the Rescheduling of Hydrocodone
Effective October 6, 2014, all Hydrocodone Combination Products are rescheduled as a Schedule II Controlled Dangerous Substance (CDS) in the State of New Jersey based on the recent federal Drug Enforcement Agency (DEA) Final Rule. Please read the following information which outlines the limitations of a Schedule II CDS medication prescription.
View Document
(9/25/14) |
A Physician's Guide to Medicinal Marijuana in New Jersey(New Jersey Department of Health)
The New Jersey Department of Health is committed to the effective implementation of the New Jersey Compassionate Use Medical Marijuana Act.
View Presentation Video |
|
Physician Information Regarding the New Jersey Department of Health Medicinal Marijuana Program
(New Jersey Department of Health)
The Department of Health Medicinal Marijuana Program (MMP) under authority of New Jersey Statute Annotated (N.J.S.A.) 24:6I-1 et seq. and New Jersey Administrative Code (N.J.A.C.) 64:8-1 et seq. is responsible for the administration and implementation of activities related to the New Jersey Compassionate Use Medical Marijuana Act.
View Document |
|
Single Dose Medication Vials
Recent outbreaks and investigations of non-hospital health care-associated infections have underscored the need to define and reinforce safe injection practices. Unsafe injection practices may result in transmission of bloodborne viruses and other microbial pathogens to patients during routine health care procedures.
View Document |
|
90-day Prescriptions of a Schedule II Controlled Dangerous Substance Approved
Under the new law, a physician may issue multiple prescriptions to a patient so that the patient may receive a total of up to a 90-day supply of a Schedule II controlled dangerous substance provided:
View Document |
|
New Law Requires Healthcare Professionals to Report Suspected Abuse, Exploitation, or Neglect of a Vulnerable Adult
View Document |
|
Medical Office Definition
View Document |
